MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $12,030.00 in Stock

MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 3,000 shares of the firm's stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $4.01, for a total value of $12,030.00. Following the transaction, the director now owns 141,950 shares in the company, valued at $569,219.50. This represents a 2.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

John Joseph Johnston also recently made the following trade(s):

• On Monday, October 28th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $3.72, for a total transaction of $11,160.00.

MaxCyte Trading Down 0.5 %

MXCT stock traded down $0.02 on Monday, hitting $4.11. The company's stock had a trading volume of 309,026 shares, compared to its average volume of 531,452. The stock has a market cap of $434.39 million, a price-to-earnings ratio of -12.09 and a beta of 1.37. The firm has a 50 day moving average of $3.77 and a two-hundred day moving average of $4.02. MaxCyte, Inc. has a 1 year low of $3.16 and a 1 year high of $5.55.

MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The business had revenue of $8.16 million during the quarter, compared to analysts' expectations of $7.50 million. During the same period in the prior year, the company earned ($0.11) earnings per share. As a group, equities analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

Large investors have recently modified their holdings of the stock. Franklin Resources Inc. acquired a new position in MaxCyte in the 3rd quarter valued at $260,000. Barclays PLC lifted its position in MaxCyte by 329.3% in the third quarter. Barclays PLC now owns 165,765 shares of the company's stock valued at $645,000 after purchasing an additional 127,156 shares during the period. Geode Capital Management LLC boosted its holdings in MaxCyte by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company's stock valued at $9,628,000 after purchasing an additional 47,960 shares in the last quarter. M&T Bank Corp increased its position in MaxCyte by 29.1% during the 3rd quarter. M&T Bank Corp now owns 113,778 shares of the company's stock worth $443,000 after purchasing an additional 25,644 shares during the period. Finally, State Street Corp raised its stake in shares of MaxCyte by 5.1% during the 3rd quarter. State Street Corp now owns 2,269,135 shares of the company's stock worth $8,827,000 after buying an additional 111,066 shares in the last quarter. Hedge funds and other institutional investors own 68.81% of the company's stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.